{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:36:09Z","timestamp":1766054169409,"version":"3.48.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100032626","name":"UNITAID","doi-asserted-by":"crossref","award":["2017-20-IMPAACT4TB"],"award-info":[{"award-number":["2017-20-IMPAACT4TB"]}],"id":[{"id":"10.13039\/100032626","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004477","name":"Stellenbosch University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004477","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40262-025-01576-3","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:47:21Z","timestamp":1760183241000},"page":"1885-1896","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy"],"prefix":"10.1007","volume":"64","clinical-trial-number":[{"clinical-trial-number":"pactr202306775627089","registry":"10.18810\/pactr"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0966-3233","authenticated-orcid":false,"given":"Saskia","family":"Janssen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanakorn","family":"Vongjarudech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats O.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caryn M.","family":"Upton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Garcia-Prats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas H.","family":"Diacon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubbe","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louvina E.","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Salazar-Austin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneke C.","family":"Hesseling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elin M.","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"1576_CR1","unstructured":"Global tuberculosis report 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240101531. Accessed 20 Dec 2024."},{"key":"1576_CR2","first-page":"392","volume":"8","author":"BJ Marais","year":"2004","unstructured":"Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8:392\u2013402.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1576_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1136\/thoraxjnl-2016-209421","volume":"72","author":"PJ Dodd","year":"2017","unstructured":"Dodd PJ, Prendergast AJ, Beecroft C, et al. The impact of HIV and antiretroviral therapy on TB risk in children: a systematic review and meta-analysis. Thorax. 2017;72:559\u201375.","journal-title":"Thorax"},{"key":"1576_CR4","unstructured":"World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018. https:\/\/iris.who.int\/handle\/10665\/260233. Accessed 31 Oct 2024."},{"key":"1576_CR5","unstructured":"WHO consolidated guidelines on tuberculosis Module 1: prevention\u2014tuberculosis preventive treatment. 2nd ed. https:\/\/www.who.int\/publications\/i\/item\/9789240096196. Accessed 25 Nov 2024."},{"key":"1576_CR6","unstructured":"Global Tuberculosis Report 2023. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023. Accessed 24 Mar 2024."},{"key":"1576_CR7","doi-asserted-by":"publisher","first-page":"857","DOI":"10.5588\/ijtld.20.0147","volume":"24","author":"M Osman","year":"2020","unstructured":"Osman M, du Preez K, Naidoo P, et al. Key changes in the public health response to TB and HIV in South Africa. Int J Tuberc Lung Dis. 2020;24:857\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1576_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","volume":"169","author":"ME Villarino","year":"2015","unstructured":"Villarino ME, Scott NA, Weis SE, et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015;169:247\u201355.","journal-title":"JAMA Pediatr"},{"key":"1576_CR9","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00737-23","volume":"67","author":"M Van Schalkwyk","year":"2023","unstructured":"Van Schalkwyk M, Bekker A, Decloedt E, et al. Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s. Antimicrob Agents Chemother. 2023;67:e00737\u201323.","journal-title":"Antimicrob Agents Chemother"},{"key":"1576_CR10","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1164\/rccm.201912-2489OC","volume":"202","author":"JE Hibma","year":"2020","unstructured":"Hibma JE, Radtke KK, Dorman SE, et al. Rifapentine population pharmacokinetics and dosing recommendations for latent tuberculosis infection. Am J Respir Crit Care Med. 2020;202:866\u201377.","journal-title":"Am J Respir Crit Care Med"},{"key":"1576_CR11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40262-020-00971-2","volume":"60","author":"SW Van Beek","year":"2021","unstructured":"Van Beek SW, Ter Heine R, Alffenaar J-WC, et al. A model-informed method for the purpose of precision dosing of isoniazid in pulmonary tuberculosis. Clin Pharmacokinet. 2021;60:943\u201353.","journal-title":"Clin Pharmacokinet"},{"key":"1576_CR12","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44:1051\u201365.","journal-title":"Clin Pharmacokinet"},{"key":"1576_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s10928-016-9487-8","volume":"43","author":"A-G Dosne","year":"2016","unstructured":"Dosne A-G, Bergstrand M, Harling K, et al. Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling. J Pharmacokinet Pharmacodyn. 2016;43:583\u201396.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1576_CR14","unstructured":"EMA. Guideline on the investigation of bioequivalence. European Medicines Agency; 2010. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 16 June 2023."},{"key":"1576_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/BF01059660","volume":"14","author":"LB Sheiner","year":"1986","unstructured":"Sheiner LB. Analysis of pharmacokinetic data using parametric models. III. Hypothesis tests and confidence intervals. J Pharmacokinet Biopharm. 1986;14:539\u201355.","journal-title":"J Pharmacokinet Biopharm"},{"key":"1576_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cmpb.2016.01.013","volume":"127","author":"C Acharya","year":"2016","unstructured":"Acharya C, Hooker AC, T\u00fcrky\u0131lmaz GY, et al. A diagnostic tool for population models using non-compartmental analysis: the ncappc package for R. Comput Methods Programs Biomed. 2016;127:83\u201393.","journal-title":"Comput Methods Programs Biomed"},{"key":"1576_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect harmacod using NONMEM. Comput Methods Programs Biomed. 2005;79:241\u201357.","journal-title":"Comput Methods Programs Biomed"},{"key":"1576_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO. Xpose\u2014an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51\u201364.","journal-title":"Comput Methods Programs Biomed"},{"key":"1576_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","volume":"101","author":"RJ Keizer","year":"2011","unstructured":"Keizer RJ, Van Benten M, Beijnen JH, et al. Pira\u00f1a and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101:72\u20139.","journal-title":"Comput Methods Programs Biomed"},{"key":"1576_CR20","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1128\/AAC.01918-13","volume":"58","author":"RM Savic","year":"2014","unstructured":"Savic RM, Lu Y, Bliven-Sizemore E, et al. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother. 2014;58:3035\u201342.","journal-title":"Antimicrob Agents Chemother"},{"key":"1576_CR21","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1002\/sim.4286","volume":"30","author":"A Dubois","year":"2011","unstructured":"Dubois A, Lavielle M, Gsteiger S, et al. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm. Stat Med. 2011;30:2582\u2013600.","journal-title":"Stat Med"},{"key":"1576_CR22","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1002\/psp4.13216","volume":"13","author":"X Chen","year":"2024","unstructured":"Chen X, Nyberg HB, Donnelly M, et al. Development and comparison of model-integrated evidence approaches for bioequivalence studies with pharmacokinetic end points. CPT Pharmacomet Syst Pharmacol. 2024;13:1734\u201347.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1576_CR23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/jpids\/pit077","volume":"3","author":"M Weiner","year":"2014","unstructured":"Weiner M, Savic RM, Kenzie WRM, et al. Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection. J Pediatr Infect Dis Soc. 2014;3:132\u201345.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"1576_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01964-18","volume":"63","author":"J Francis","year":"2019","unstructured":"Francis J, Zvada SP, Denti P, et al. A population pharmacokinetic analysis shows that Arylacetamide Deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of rifapentine. Antimicrob Agents Chemother. 2019;63:e01964\u201318.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1576_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/cid\/ciab908","volume":"75","author":"P Denti","year":"2022","unstructured":"Denti P, Wasmann RE, Van Rie A, Winckler J, Bekker A, Rabie H, Hesseling AC, van der Laan LE, Gonzalez-Martinez C, Zar HJ, Davies G. Optimizing dosing and fixed-dose combinations of rifampicin, isoniazid, and pyrazinamide in pediatric patients with tuberculosis: a prospective population pharmacokinetic study. Clin Infect Dis. 2022;75(1):141\u201351.","journal-title":"Clin Infect Dis"},{"key":"1576_CR26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02376-19","volume":"64","author":"T Mthiyane","year":"2020","unstructured":"Mthiyane T, Millard J, Adamson J, et al. N-acetyltransferase 2 genotypes among Zulu-speaking South Africans and isoniazid and N-acetyl-isoniazid pharmacokinetics during antituberculosis treatment. Antimicrob Agents Chemother. 2020;64:e02376\u201319.","journal-title":"Antimicrob Agents Chemother"},{"key":"1576_CR27","unstructured":"Prifitin (rifapentine) tablets. Product label. Silver Spring, MD U.S. Food and Drug Administration; 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021024s011lbl.pdf. Accessed 31 Oct 2024."},{"key":"1576_CR28","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1128\/AAC.41.12.2670","volume":"41","author":"CA Peloquin","year":"1997","unstructured":"Peloquin CA, Jaresko GS, Yong CL, et al. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother. 1997;41:2670\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1576_CR29","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.5588\/ijtld.18.0775","volume":"23","author":"R Court","year":"2019","unstructured":"Court R, Chirehwa MT, Wiesner L, et al. Effect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23:1068\u201374.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1576_CR30","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ijid.2022.07.040","volume":"122","author":"W Phaisal","year":"2022","unstructured":"Phaisal W, Jantarabenjakul W, Wacharachaisurapol N, et al. Pharmacokinetics of isoniazid and rifapentine in young pediatric patients with latent tuberculosis infection. Int J Infect Dis. 2022;122:725\u201332.","journal-title":"Int J Infect Dis"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01576-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01576-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01576-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:32:42Z","timestamp":1766053962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01576-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1576"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01576-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by UNITAID through the IMPACT4TB project grant 2017-20-IMPAACT4TB awarded to Aurum.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Elin M. Svensson is an Editorial Board member of Clinical Pharmacokinetics but was not involved in the selection of peer reviewers or in any subsequent editorial decisions related to this manuscript. The other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The study was approved by the Stellenbosch University Health Research Ethics Committee (reference number 26169), the South African Health Products Regulatory Authority (Trial Reference 20220905) and the WHO Ethical Review Committee (Reference ERC.0003837) prior to initiation. The trial is registered with the Pan African Clinical Trials Registry (PACTR202306775627089).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All adults provided written informed consent in the home language of their choice prior to their inclusion in the studies. No personally identifiable information is presented in this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All participants provided consent for publication","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data will be made available upon reasonable request to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"The code used for the final model is provided in ESM S2 for the rifapentine model and in ESM S3 for the isoniazid model.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"S. Janssens coordinated the study, contributed to the study design, and drafted the manuscript. T. Vongjarudech was responsible for conducting the modelling and analysis and contributed to drafting the manuscript. A.C. Hessling and E.M. Svensson contributed to the study design and analysis and provided supervision. All authors have approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}